As the first and only FDA approved antiviral treatment for COVID-19, Gilead’s remdesivir has been shown to prevent individuals at high risk of severe disease from being hospitalized. However, inherent eligibility and accessibility restrictions reduce its effectiveness in the larger population.
The Challenges of Treating COVID-19: Lessons from Gilead’s Remdesivir
